DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Ubicación actual:
> This Story

Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

New proton therapy center planned in Russia Investment calls for 7.5 billion rubles to bring greater cancer care to patients

NYC proton facility opens for business $300 million dollar, 140,000 square-foot facility was ten years in the making

Bill aiming to reduce prior authorization delays for cancer treatment introduced in Congress Supporting timely access to care

Roche and GE Healthcare release NAVIFY Tumor Board 2.0 Supports personalized treatment decision-making

Cancer mortality for men, women and children on the decline, says report Decreased by 1.8 percent in men and 1.4 percent in women

Japanese startup to develop ultra-compact proton therapy system Designed to replace conventional radiotherapy systems

FDA okays Philips' MR-only radiotherapy simulator, MRCAT pelvis Create treatment plans for bladder, rectal, anal and cervical cancer

Varian to acquire Cancer Treatment Services International for $283 million Enables production of multidisciplinary solutions

Varian acquires CyberHeart, enters cardiac radioablation market Emerging technology could benefit treatment of irregular heartbeats

New 12-year study highlights value of PRRT, based on long-term outcomes Understanding peptide receptor radionuclide therapy

ASTRO members are asking Congress
to help safeguard radiotherapy
treatment policies

Radiation oncologists appeal to Congress to safeguard radiotherapy treatment

por John R. Fischer , Staff Reporter
Radiation oncologists and members of the American Society for Radiation Oncology (ASTRO) gathered on Capitol Hill this week to request congressional support for policies designed to protect access for cancer patients to high-quality, value-based care.

Meeting with policymakers on ASTRO Advocacy Day, the clinicians brought up a number of legislative priorities that they claim require greater attention, protection and improvement.

Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

One such topic was the current payment model exercised in healthcare settings for value-based care, which has garnered much concern due to the upcoming expiration of a payment freeze by the Centers for Medicare and Medicaid Services that prevents cuts to reimbursements through the end of 2019.

"Policymakers increasingly recognize the potential advantages of episode-based payment models relative to fee-for-service structures, but radiation oncologists are not yet able to fully participate in this transition to value-based health care," Dr. Paul Harari, chair of the ASTRO board of directors, told HCB News. "For Medicare patients the only quality payment program available now for radiation oncologists is the Merit-based Incentive Payment System (MIPS), and ASTRO members feel that the current reporting burdens of MIPS leads to inefficiencies without improving quality of care for patients."

Harari and his fellow members instead suggested the implementation of an episode-based APM for radiation oncology that would drive adherence to clinical guidelines by incentivizing radiation oncologists to abide by guideline-concordant care episodes, thereby improving cancer patient care and stabilizing reimbursements, especially for providers of Medicare, of which most American patients are beneficiaries. The idea for such a model stems from a proposal made in 2017 to incentivize radiation oncologists to abide by nationally respected guidelines for treating five of the most common cancers with radiotherapy. They include breast, lung, prostate, colorectal, and head and neck.

They also called for an end to unnecessary prior authorizations, seeing them as hindrances that prevent radiation oncologists from providing patients with the best course of action, despite being held accountable for the outcomes of treatments. A recent survey completed by ASTRO members found that 93 percent of radiation oncologists found their patients experienced delays in treatment due to prior authorization, with 31 percent experiencing delays longer than five days, the equivalent of a full week of standard radiation treatment. The main causes were found to be demands on radiation oncologists to generate multiple treatment plans; peer-to-peer reviews by non-experts in radiation oncology (including non-doctors sometimes); and the appeals process to overturn a substantial majority of denials for radiation therapy.
  Pages: 1 - 2 >>

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Recently Certified
Ver usuarios certificados recientemente
Recently Rated
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Service Technicians Forum
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2019, Inc.